NO20070345L - Use of DNA molecule as a vaccine adjuvant - Google Patents

Use of DNA molecule as a vaccine adjuvant

Info

Publication number
NO20070345L
NO20070345L NO20070345A NO20070345A NO20070345L NO 20070345 L NO20070345 L NO 20070345L NO 20070345 A NO20070345 A NO 20070345A NO 20070345 A NO20070345 A NO 20070345A NO 20070345 L NO20070345 L NO 20070345L
Authority
NO
Norway
Prior art keywords
dna molecule
vaccine
fragment
variant
host cell
Prior art date
Application number
NO20070345A
Other languages
Norwegian (no)
Inventor
Audun Helge Nerland
Niels Lorenzen
Ingunn Sommerset
Original Assignee
Forinnova As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413973A external-priority patent/GB0413973D0/en
Priority claimed from GB0414091A external-priority patent/GB0414091D0/en
Application filed by Forinnova As filed Critical Forinnova As
Publication of NO20070345L publication Critical patent/NO20070345L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/30011—Nodaviridae
    • C12N2770/30034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer anvendelse av et DNA-molekyl som koder for et antigen (og spesielt som koder for et bakterie- eller virus-glykoprotein, fortrinnsvis et rhabdovirus-glykoprotein) som uttrykkes på overflaten av en vertscelle, eller en variant, eller et fragment derav, ved fremstilling av et medikament for anvendelse som vaksineadjuvans eller for å forsterke de immunstimulerende egenskaper eller vaksinasjonsegenskapene hos et vaksinemolekyl, eller for å forsterke immunresponsen overfor et vaksinemolekyl. Et preparat omfattende nevnte DNA-molekyl som koder for et antigen som uttrykkes på overflaten av en vertscelle, eller en variant, eller et fragment derav, og et vaksinemolekyl, er også tilveiebrakt. Et ytterligere aspekt ved foreliggende oppfinnelse tilveiebringer anvendelse av DNA-molekylet som koder for et antigen som uttrykkes på overflaten av en vertscelle, eller en variant, eller et fragment derav, ved fremstilling av et preparat som kan forbedre eller øke elimineringen av andre fremmede DNA-molekyler fra en organisme.The present invention provides the use of a DNA molecule encoding an antigen (and in particular, encoding a bacterial or viral glycoprotein, preferably a rhabdovirus glycoprotein) expressed on the surface of a host cell, or a variant, or a fragment thereof. , in the manufacture of a medicament for use as a vaccine adjuvant or to enhance the immunostimulatory or vaccination properties of a vaccine molecule, or to enhance the immune response to a vaccine molecule. A composition comprising said DNA molecule encoding an antigen expressed on the surface of a host cell, or a variant, or a fragment thereof, and a vaccine molecule, is also provided. A further aspect of the present invention provides the use of the DNA molecule encoding an antigen expressed on the surface of a host cell, or a variant, or a fragment thereof, in the preparation of a composition capable of enhancing or enhancing the elimination of other foreign DNA. molecules from an organism.

NO20070345A 2004-06-22 2007-01-18 Use of DNA molecule as a vaccine adjuvant NO20070345L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0413973A GB0413973D0 (en) 2004-06-22 2004-06-22 Use
GB0414091A GB0414091D0 (en) 2004-06-23 2004-06-23 Use
PCT/GB2005/002472 WO2005123121A2 (en) 2004-06-22 2005-06-22 Use of dna molecule as vaccine adjuvant

Publications (1)

Publication Number Publication Date
NO20070345L true NO20070345L (en) 2007-03-02

Family

ID=34981463

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070345A NO20070345L (en) 2004-06-22 2007-01-18 Use of DNA molecule as a vaccine adjuvant

Country Status (4)

Country Link
EP (1) EP1784208A2 (en)
CA (1) CA2572171A1 (en)
NO (1) NO20070345L (en)
WO (1) WO2005123121A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100436599C (en) * 2006-05-12 2008-11-26 中国水产科学研究院黄海水产研究所 Female-specific AFLP fragment of Cynoglossus semilaevis Gunther and PCR method for identification of genetic sex
CN101914529B (en) * 2010-07-29 2012-03-14 中国水产科学研究院黄海水产研究所 Cynoglossus semilaevis gunther sex-linked microsatellite marker and genetics sex testing method

Also Published As

Publication number Publication date
CA2572171A1 (en) 2005-12-29
WO2005123121A2 (en) 2005-12-29
WO2005123121A3 (en) 2006-06-15
EP1784208A2 (en) 2007-05-16

Similar Documents

Publication Publication Date Title
Gauger et al. Live attenuated influenza A virus vaccine protects against A (H1N1) pdm09 heterologous challenge without vaccine associated enhanced respiratory disease
NO20072470L (en) Malaria Initiator / amplifier vaccine
ATE494906T1 (en) CELL-DERIVED VIRAL VACCINES WITH LOW AMOUNTS OF RESIDUAL CELL DNA
DK1898948T3 (en) Polyriboinosinic acid-polyribocytidylic acid-based adjuvant
NO20090194L (en) Recombinant viral vaccine
WO2011146933A3 (en) Universal dengue virus sequences and methods of use
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
JP2014507146A5 (en)
MX2019003682A (en) Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same.
WO2006136460A8 (en) New adjuvant
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
Whitlock et al. Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge
Gasmi et al. A global survey in the developmental landscape of possible vaccination strategies for COVID-19
WO2009074861A3 (en) Improved vaccine
WO2006076587A3 (en) Peptides for delivery of mucosal vaccines
NO20070345L (en) Use of DNA molecule as a vaccine adjuvant
TW201938578A (en) Enterovirus vaccine
WO2008082719A3 (en) Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2003095480A3 (en) Brachyspira hyodysenteriae vaccine
ATE450545T1 (en) LAWSONIA INTRACELLULARIS SUBUNIT VACCINE
NO20081541L (en) New sea lice vaccine
WO2004007726A3 (en) Brachyspira hyodysenteriae vaccine
TW202317600A (en) Multivalent vaccine for protection against multiple virus infection
WO2009071613A3 (en) Vaccine
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application